Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

20166,327 citationsletterbronze Open Access

Authors

Steven P. Marso · Research Medical Center

Stephen C. Bain · Swansea University

Agostino Consoli · Swansea University

Freddy G. Eliaschewitz · Swansea University

Esteban Jódar · Universidad Europea de Madrid

Lawrence A. Leiter · St. Michael's Hospital

Ildiko Lingvay ·

Abstract

In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide. (Funded by Novo Nordisk; SUSTAIN-6 ClinicalTrials.gov number, NCT01720446 .).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 19, pp. 1834-1844

DOI: 10.1056/nejmoa1607141

Field-Weighted Citation Impact: 393.74